title: Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases.
abstract: Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) represent a heterogeneous group of malignant lymphoid tumors, which have distinct histological and/or biological characteristics with preferential nodal involvement. However, none of the previous studies have assessed the prevalence of common NHL and HL subtypes at each nodal site of involvement. The aim of our study was to determine the prevalence of HL and NHL subtypes depending on their nodal sites of involvement.We conducted a single-center retrospective study of 938 lymphoma cases diagnosed in the Pathology Department of Toulouse Purpan Hospital in France between 2001 and 2008, taking into account the site that corresponded to the diagnostic biopsy. The most frequent sites were cervical lymph nodes (36.8% of all cases), inguinal lymph nodes (16.4%), axillary lymph nodes (11.9%), and supraclavicular lymph nodes (11%). We found an unexpected association between intraparotid nodes and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and between inguinal nodes and follicular lymphoma. The risk of having classical Hodgkin lymphoma (CHL) was 15 times greater in patients with mediastinal lymphoma compared to those with other sites of involvement. Regarding HL, nodal and extranodal mediastinal sites and supraclavicular nodes were more likely to be involved by nodular sclerosis Hodgkin lymphoma (NSCHL). In addition, intra-abdominal lymph nodes were more frequently involved by lymphocyte depleted Hodgkin lymphoma compared to inguinal nodes where NLPHL predominated.Our study shows that some lymph node sites have a disproportionate prevalence of specific subtypes of lymphoma. Identifying these sites may aid to diagnose and better elucidate the pathogenesis of these tumors.
authors.affiliation: From the Département de Pathologie, Institut Universitaire du Cancer-Oncopole de Toulouse (CL, CD, GRdP, PB); Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037 (CL, PB); Université Toulouse III Paul-Sabatier (CL, PB); Laboratoire d'Excellence 'TOUCAN', Toulouse, France (CL, PB); Institute for Cancer Genetics, Columbia University, New York, NY (CD); UCSF School of Medicine, Department Neurology, San Francisco, CA, USA (P-AG); and Laboratoire d'Anatomie Pathologique, CHU Besançon et Université de Franche-Comté, France (SV).
authors.forename: Camille
authors.initials: C
authors.lastname: Laurent
authors.forename: Catherine
authors.initials: C
authors.lastname: Do
authors.forename: Pierre-Antoine
authors.initials: PA
authors.lastname: Gourraud
authors.forename: Geisilene Russano
authors.initials: GR
authors.lastname: de Paiva
authors.forename: Séverine
authors.initials: S
authors.lastname: Valmary
authors.forename: Pierre
authors.initials: P
authors.lastname: Brousset
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005602:France / Q000453:epidemiology; D006689:Hodgkin Disease / Q000453:epidemiology* / Q000473:pathology*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000473:pathology*; D008297:Male; D008482:Mediastinum / Q000473:pathology; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies